The Biodrug Revolution

Whilst excitement about biologics-based therapeutics is high, Biodrugs remain hard to produce at a large scale, while ensuring targeted Critical Quality Attributes (CQAs) are maintained. Bioproduction remains highly complex, mostly due to the nature of the bioproduct itself (mRNA stability, mAb folding, and protein glycosylation, for example) or the difficulty in deploying powerful monitoring sensors that enable full control of bioprocesses at scale.

Existing bioprocesses usually rely on conventional batch processing which comes with size and time limitations. To boost the potential of Biodrugs to improve human health, bioprocesses need to be scalable and their challenges must be simplified. Challenges are mostly technological, and many can be improved through a joined-up approach to digital technology, incorporating better data collection and processing using cutting edge tools. As Biodrugs become more and more complex, biotechnologies and cutting-edge technologies have to be considered in one holistic approach, combining omics know-how and AI within multi-functional teams. The implementation of this new methodology has already saved time and cost, reducing the time to market, and ultimately improving health and saving lives.



Request Free!

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.